Sihuan Pharmaceutical Announces Major AI Partnership with dProtein: Strategic Expansion in Medical Aesthetics and Innovative Drug Development
Key Highlights for Investors
- Strategic Joint Venture: Sihuan Pharmaceutical Holdings Group Ltd. (“Sihuan Pharmaceutical”) has formally signed a cooperation agreement with dProtein Pharmaceutical Biotechnology (Beijing) Co., Ltd. (“dProtein”). This follows the earlier framework agreement in September 2025. The two parties will jointly establish a new joint venture company (“JV Company”), which will be led and majority-controlled by Sihuan Pharmaceutical.
- AI Integration Across Medical Aesthetics Value Chain: The JV Company aims to deeply integrate artificial intelligence (AI) into the medical aesthetics industry, with a focus on R&D, production, and sales. The objective is to develop novel medical aesthetics materials (e.g., biomacromolecules, polymers) and products, driven by AI technology.
- Comprehensive Scope: The cooperation will cover:
- AI-driven material and product innovation (including research on composition, material formulation, injection protocols, tissue response prediction, and real-world data-based product optimization).
- Clinical research and risk control (AI models to enhance injection safety and risk management).
- Industrial empowerment and ecosystem development (AI tools for patient diagnosis, treatment planning, and professional doctor training to elevate industry service levels).
- Expansion into Biopharmaceuticals: The JV Company and dProtein will jointly explore AI-driven design and development of novel protein and nucleic acid drugs, targeting new growth areas.
- Strategic Investment: Sihuan Pharmaceutical has participated in dProtein’s Pre-A round financing, becoming a strategic investor. This move strengthens the capital and business links, positioning both companies to share future development achievements.
- Technological Advantage: The partnership combines Sihuan’s industrial resources, commercialization channels, and R&D pipeline reserves with dProtein’s proprietary AI-driven Deep Protein Space Engine (ADPSE) platform. The goal is to create an intelligent R&D closed-loop, breaking bottlenecks in high-end medical aesthetics materials, reducing costs, shortening development cycles, and enhancing product innovation success rates.
- Market Leadership: Sihuan Pharmaceutical is an established leader in medical aesthetics and pharmaceuticals in China, with nearly a decade of experience, a complete business chain, and a strong market share in light medical aesthetics products.
- Listing Rules Implications: The JV Company and Financing do not constitute connected or disclosable transactions under Hong Kong Listing Rules, as all percentage ratios are below 5% and dProtein is independent from Sihuan and its connected persons.
Potentially Price-Sensitive Information
- Strategic Move: The formation of the JV Company and strategic investment in dProtein could significantly enhance Sihuan’s core competitiveness in the medical aesthetics market, accelerate innovation, and open new growth avenues in biopharmaceuticals. These developments have the potential to positively impact future earnings and market positioning.
- AI Integration: The focus on leveraging AI for product innovation and risk management could reduce R&D costs and development cycles, potentially improving margins and boosting revenue from new products.
- Industry Leadership: Sihuan’s efforts to build a closed-loop intelligent R&D platform, combined with dProtein’s AI expertise, may lead to differentiated products and strengthen its market share, which is price-sensitive information for shareholders.
- No Connected Transaction: The JV Company and Financing are not connected or disclosable transactions, which means no regulatory hurdles or delays are expected.
About Sihuan Pharmaceutical
Founded in 2001 and listed on the Hong Kong Stock Exchange since 2010, Sihuan Pharmaceutical is a leading innovation-driven medical aesthetics and pharmaceutical company. It operates a full-chain business model across raw materials, products, and commercialization, serving the Chinese medical aesthetics market and striving to become a global leader in the sector.
About dProtein
dProtein is a cutting-edge AI-driven protein design company, with a team of top talents in protein engineering and AI. Its proprietary ADPSE platform automates molecular design workflows and is positioned at the intersection of AI and life sciences.
Conclusion
The strategic partnership and joint venture between Sihuan Pharmaceutical and dProtein represent a significant step forward in the integration of AI technology within the medical aesthetics and biopharmaceutical industries. This move is likely to have a positive impact on Sihuan’s competitiveness, innovation pipeline, and long-term shareholder value. Investors should monitor further developments, as successful execution could drive share price appreciation.
Disclaimer
The information provided in this article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence before making any investment decision. The announcement does not serve as an advertisement for any medicine, surgical appliance, treatment, or orally consumed product.
